Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Leukemia, Myeloid, Acute 245Precursor Cell Lymphoblastic Leukemia-Lymphoma 143Myelodysplastic Syndromes 142Leukemia, Lymphocytic, Chronic, B-Cell 139Leukemia 127Multiple Myeloma 117Lymphoma 115Lymphoma, Non-Hodgkin 112Recurrence 79Hematologic Neoplasms 74Melanoma 68Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Hodgkin Disease 67Lymphoma, B-Cell 61Lymphoma, Mantle-Cell 51Lymphoma, Large B-Cell, Diffuse 50Lymphoma, Follicular 50Burkitt Lymphoma 41Ovarian Neoplasms 40Neoplasms 39Myeloproliferative Disorders 39Neoplasm Metastasis 34Lymphoma, B-Cell, Marginal Zone 30Graft vs Host Disease 29Neoplasms, Plasma Cell 28Carcinoma, Non-Small-Cell Lung 27Breast Neoplasms 27Leukemia, Biphenotypic, Acute 25Primary Myelofibrosis 24Anemia, Refractory, with Excess of Blasts 23

Interventions

bintrafusp alfa protein, human 3Radiotherapy 3Cisplatin 3pembrolizumab 2Gemcitabine 2vactosertib 1fresolimumab 1fludarabine 1enzalutamide 1ascrinvacumab 1Trabedersen 1Temozolomide 1Sorafenib 1Radiotherapy, Intensity-Modulated 1Paclitaxel 1Losartan 1Lomustine 1LY3300054 1LY-2157299 1Fenretinide 1Drug Delivery Systems 1Cyclophosphamide 1Carboplatin 1Bevacizumab 1Anastrozole 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Camurati-Engelmann Syndrome × fludarabine × Clear all
NCT02065362 2026-01-29

TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

Baylor College of Medicine

Phase 1 Active not recruiting
14 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡